Expand FATE Menu
FATE MENU

FATE Latest Press Releases

-- August 3, 2026 --

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 9, 2026 --

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate Globe Newswire 8:30 AM

-- July 6, 2026 --

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting Globe Newswire 8:30 AM

-- July 1, 2026 --

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences Globe Newswire 4:05 PM

-- June 30, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 9:00 AM

-- June 15, 2026 --

Fate Therapeutics Appoints Laura Hamill to Board of Directors Globe Newswire 8:30 AM

-- June 12, 2026 --

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell Globe Newswire 8:10 AM

-- June 8, 2026 --

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet Globe Newswire 9:01 AM

-- June 4, 2026 --

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting Globe Newswire 8:30 AM

-- June 2, 2026 --

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 1, 2026 --

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting Globe Newswire 8:30 AM

-- May 21, 2026 --

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases Globe Newswire 8:30 AM

-- May 13, 2026 --

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates Globe Newswire 8:30 AM

-- May 11, 2026 --

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting Globe Newswire 8:30 AM

-- May 5, 2026 --

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 Globe Newswire 8:30 AM

-- May 4, 2026 --

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases Globe Newswire 9:00 AM

-- May 1, 2026 --

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- April 30, 2026 --

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting Globe Newswire 9:00 AM

-- April 16, 2026 --

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting Globe Newswire 9:00 AM

-- April 9, 2026 --

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences Globe Newswire 9:00 AM

-- April 2, 2026 --

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- March 18, 2026 --

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed Globe Newswire 11:30 AM
Market Data Delayed 15 Minutes